Fudan-Zhangjiang(SH:688505)2025-01-17 10:20Financial Performance Forecast - The company expects a net profit attributable to shareholders of RMB 35 million to RMB 52 million for the year 2024, representing a decrease of RMB 56.63 million to RMB 73.63 million, or a decline of 52.13% to 67.78% compared to the previous year[3]. - The projected net profit attributable to shareholders after deducting non-recurring gains and losses is expected to be between RMB -2 million and RMB 17 million, a decrease of RMB 52.89 million to RMB 71.89 million, or a decline of 75.68% to 102.86% year-over-year[3]. - In the previous year, the net profit attributable to shareholders was RMB 108.63 million, with a total profit of RMB 97.53 million[4]. - The company emphasizes that the performance forecast is based on preliminary calculations and has not been audited by certified public accountants[6]. - Investors are advised to exercise caution and consider the preliminary nature of the forecast data until the audited annual report is released[7]. Research and Development - The company has significantly increased its R&D expenses, with an increase of approximately RMB 70 million compared to the previous year, driven by the advancement of multiple R&D projects[5]. - The FDA018 antibody-drug conjugate project has entered Phase III clinical trials, with over 40 clinical trial centers initiated and the first patient enrolled in August 2024[5]. - The FZ-AD005 antibody-drug conjugate project has entered Phase I clinical trials, with the first patient enrolled in July 2024[5]. - The company's wholly-owned subsidiary has officially started operations at a new ADC production facility and successfully scaled up production processes for two ADC projects[5].